@entity21193 and @entity3118 : a new XXXX -reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.

@entity1 @entity137 @entity3118 @entity2132 @entity21193
New conditioning regimens are being explored to reduce @entity137 and enable allogeneic bone marrow transplantation in @entity1 not eligible for conventional transplantation. We have investigated @entity21193 , an alkylating agent, with the aim of developing an efficient and reliable but less-toxic conditioning regimen. A series of 30 @entity1 who were not eligible for standard conditioning therapy received transplants from HLA-matched related (n = 14) or unrelated (n = 16) donors after administration of @entity21193 10 g/m2 intravenously daily for 3 days and @entity3118 30 mg/m2 intravenously daily for 5 days. @entity1 receiving grafts from unrelated donors also were given rabbit antithymocyte globulin 10 mg/kg intravenously daily for 3 days. All @entity1 achieved prompt neutrophil and platelet recovery. @entity137 was generally mild with Common @entity137 Criteria (CTC) grade 3 or 4 attributable to the conditioning seen only with transaminases. Complete donor chimerism was achieved by 90% of the @entity1 . @entity2132 ( @entity2132 ) grade III or IV developed in 14% of the @entity1 and chronic @entity2132 in 39%. An estimated overall survival rate of 73% and an event-free survival rate of 49% have been reached after a median of 22 months (range, 7.4-33.4 months). In summary, the combination of @entity21193 and @entity3118 is a safe and efficient conditioning regimen.
